Advertisement
Canada markets closed

  • S&P/TSX

    22,465.37
    +165.57 (+0.74%)
     

  • S&P 500

    5,308.13
    +4.86 (+0.09%)
     

  • DOW

    39,806.77
    -196.82 (-0.49%)
     

  • CAD/USD

    0.7340
    -0.0008 (-0.11%)
     

  • CRUDE OIL

    79.65
    -0.15 (-0.19%)
     

  • Bitcoin CAD

    94,989.36
    +4,681.52 (+5.18%)
     

  • CMC Crypto 200

    1,467.01
    +112.60 (+8.31%)
     

  • GOLD FUTURES

    2,430.30
    +12.90 (+0.53%)
     

  • RUSSELL 2000

    2,102.50
    +6.78 (+0.32%)
     

  • 10-Yr Bond

    4.4370
    +0.0170 (+0.38%)
     

  • NASDAQ

    16,794.88
    +108.91 (+0.65%)
     

  • VOLATILITY

    12.15
    +0.16 (+1.33%)
     

  • FTSE

    8,424.20
    +3.94 (+0.05%)
     

  • NIKKEI 225

    39,069.68
    +282.30 (+0.73%)
     

  • CAD/EUR

    0.6757
    +0.0002 (+0.03%)
     

CORRECTED-Novavax erases doubts about its ability to remain in business

Reuters
·1 min read

(Corrects 2nd paragraph to clarify notice was from 2023)

May 10 (Reuters) - COVID-19 vaccine maker Novavax , on Friday, erased doubts about its ability to remain in business by removing a so-called "going concern" notice.

In February last year, Novavax had raised doubts about its ability to remain in business and announced plans to slash spending as it worked to prepare for a fall vaccination campaign.

The company also said on Friday that its revenue rose to $94 million in the first quarter, from $81 million in the same period in 2023. (Reporting by Utkarsh Shetti in Bengaluru; Editing by Savio D'Souza)